Loading
Products by development stage for any of 139 targets, every modality class and every cancer, with the phase 2 and 3 studies registered for them. Below, a crowding index: active assets per 100,000 addressable patients a year, currently led by KIT, BCR::ABL1 (Philadelphia chromosome), NTRK.
Registry counts are ClinicalTrials.gov phase 2 and 3 studies naming each product (fetched 2026-09-28); a combination study counts once per product it names, so sums overstate distinct trials.
KIT 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 11 | 3 | 2,468 | 1k (663 to 2k) | 1055.01* | |
BCR::ABL1 (Philadelphia chromosome) 1 cancer with incidence and prevalence data | 8 | 0 | 593 | 19k (8k to 29k) | 42.64 | |
NTRK 6 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 4 | 0 | 51 | 13k (6k to 21k) | 37.14* | |
mTOR 1 cancer with incidence and prevalence data | 2 | 0 | 1,231 | 12k (9k to 14k) | 25.89 | |
FGFR2 4 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 8 | 4 | 1,146 | 65k (32k to 97k) | 23.25* | |
VEGF / VEGFR 1 cancer with incidence and prevalence data · partial: 2 without a GLOBOCAN estimate | 22 | 4 | 9,347 | 136k (98k to 174k) | 21.34* | |
FLT3 1 cancer with incidence and prevalence data | 5 | 0 | 159 | 32k (21k to 44k) | 18.59 | |
Retinoic acid receptor alpha (RARA) 1 cancer with incidence and prevalence data | 2 | 0 | 114 | 11k (8k to 15k) | 17.46 | |
MDM2 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 0 | 1 | 20 | 15k (15k to 15k) | 13.61* | |
CDK4/6 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 5 | 3 | 682 | 68k (34k to 103k) | 13.14* | |
KMT2A (MLL) rearrangement 2 cancers with incidence and prevalence data | 2 | 0 | 1,564 | 15k (6k to 24k) | 13.08 | |
MET 5 cancers with incidence and prevalence data | 11 | 5 | 525 | 171k (105k to 236k) | 12.89 | |
Topoisomerase II alpha (TOP2A) 1 cancer with incidence and prevalence data | 0 | 1 | 113 | 40k (24k to 56k) | 12.44 | |
RET 4 cancers with incidence and prevalence data | 8 | 1 | 1,048 | 80k (39k to 122k) | 12.42 | |
ROS1 2 cancers with incidence and prevalence data | 6 | 0 | 139 | 53k (32k to 74k) | 11.27 | |
LAG-3 1 cancer with incidence and prevalence data | 1 | 2 | 137 | 39k (25k to 53k) | 10.26 | |
BTK (Bruton tyrosine kinase) 1 cancer with incidence and prevalence data | 5 | 3 | 757 | 84k (49k to 119k) | 9.52 | |
ALK 4 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 9 | 1 | 309 | 124k (73k to 176k) | 8.84* | |
BCMA 1 cancer with incidence and prevalence data | 8 | 2 | 210 | 170k (152k to 188k) | 8.24 | |
CD19 3 cancers with incidence and prevalence data | 12 | 4 | 374 | 329k (220k to 438k) | 7.9 | |
Somatostatin receptor 2 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 5 | 3 | 187 | 127k (77k to 177k) | 7.08* | |
PD-1 2 cancers with incidence and prevalence data | 17 | 4 | 7,318 | 493k (248k to 738k) | 6.49 | |
IDH1 / IDH2 4 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 5 | 3 | 100 | 133k (91k to 176k) | 6.01* | |
Menin 2 cancers with incidence and prevalence data | 2 | 0 | 19 | 38k (23k to 54k) | 5.24 | |
CD20 2 cancers with incidence and prevalence data | 8 | 1 | 2,699 | 259k (178k to 341k) | 5.01 | |
HER2 16 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 19 | 15 | 2,835 | 826k (475k to 1.2m) | 4.96* | |
EZH2 1 cancer with incidence and prevalence data · partial: 2 without a GLOBOCAN estimate | 0 | 1 | 50 | 42k (28k to 55k) | 4.79* | |
CD25 (IL-2 receptor alpha) 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 1 | 1 | 36 | 44k (41k to 48k) | 4.52* | |
CD22 1 cancer with incidence and prevalence data | 1 | 0 | 59 | 67k (37k to 97k) | 4.45 | |
PRAME 1 cancer with incidence and prevalence data | 0 | 2 | 5 | 45k (24k to 66k) | 4.43 | |
AKT 3 cancers with incidence and prevalence data | 3 | 1 | 680 | 101k (51k to 151k) | 3.95 | |
Claudin 18.2 2 cancers with incidence and prevalence data | 2 | 5 | 58 | 425k (268k to 582k) | 3.76 | |
Estrogen receptor (ERα) 2 cancers with incidence and prevalence data | 14 | 2 | 2,304 | 443k (268k to 618k) | 3.61 | |
PARP 4 cancers with incidence and prevalence data | 6 | 2 | 687 | 251k (187k to 314k) | 3.59 | |
Interleukin-6 and IL-6 receptor 1 cancer with incidence and prevalence data | 2 | 0 | 348 | 61k (56k to 66k) | 3.29 | |
BRAF 10 cancers with incidence and prevalence data | 12 | 0 | 1,187 | 399k (212k to 586k) | 3.26 | |
Androgen receptor 5 cancers with incidence and prevalence data | 11 | 2 | 1,277 | 519k (225k to 813k) | 3.08 | |
PD-L1 8 cancers with incidence and prevalence data | 12 | 9 | 2,304 | 937k (664k to 1.2m) | 2.56 | |
BRCA1 / BRCA2 (HRD) 12 cancers with incidence and prevalence data | 5 | 0 | 497 | 204k (109k to 299k) | 2.45 | |
CD52 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 1 | 0 | 263 | 84k (49k to 119k) | 2.38* | |
CD123 1 cancer with incidence and prevalence data | 2 | 0 | 16 | 87k (58k to 117k) | 2.29 | |
Nectin-4 2 cancers with incidence and prevalence data | 1 | 0 | 82 | 175k (102k to 249k) | 2.28 | |
PSMA 3 cancers with incidence and prevalence data | 6 | 7 | 127 | 719k (440k to 998k) | 2.09 | |
CD38 2 cancers with incidence and prevalence data | 2 | 1 | 424 | 253k (201k to 305k) | 1.97 | |
EGFR 12 cancers with incidence and prevalence data | 27 | 7 | 3,655 | 2.4m (1.5m to 3.2m) | 1.88 | |
GPRC5D 1 cancer with incidence and prevalence data | 1 | 1 | 28 | 123k (96k to 150k) | 1.62 | |
PRMT5 (MTAP-deleted cancers) 4 cancers with incidence and prevalence data | 0 | 1 | 14 | 365k (314k to 417k) | 1.37 | |
BCL-2 2 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 2 | 0 | 600 | 147k (86k to 208k) | 1.36* | |
CD70 2 cancers with incidence and prevalence data | 0 | 0 | 5 | 171k (112k to 230k) | 1.17 | |
CD47 2 cancers with incidence and prevalence data | 0 | 1 | 39 | 285k (202k to 368k) | 1.05 | |
B7-H3 2 cancers with incidence and prevalence data | 0 | 4 | 39 | 487k (331k to 644k) | 1.03 | |
PIK3CA / PI3K-alpha 10 cancers with incidence and prevalence data | 8 | 2 | 887 | 1.1m (600k to 1.6m) | 0.99 | |
DLL3 2 cancers with incidence and prevalence data | 1 | 2 | 47 | 507k (361k to 653k) | 0.99 | |
WRN helicase (MSI-high cancers) 3 cancers with incidence and prevalence data | 0 | 0 | 2 | 277k (227k to 328k) | 0.72 | |
Folate receptor alpha 3 cancers with incidence and prevalence data | 2 | 4 | 56 | 1.2m (951k to 1.5m) | 0.58 | |
HER3 4 cancers with incidence and prevalence data | 2 | 3 | 408 | 1.5m (1.1m to 1.9m) | 0.53 | |
KRAS 22 cancers with incidence and prevalence data | 11 | 7 | 152 | 5.0m (3.9m to 6.1m) | 0.48 | |
TROP2 6 cancers with incidence and prevalence data | 3 | 0 | 280 | 1.7m (1.2m to 2.1m) | 0.42 | |
Smoothened (hedgehog pathway) 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 3 | 1 | 109 | 1.0m (1.0m to 1.0m) | 0.38* | |
CEACAM5 3 cancers with incidence and prevalence data | 0 | 3 | 24 | 1.4m (1.0m to 1.7m) | 0.22 | |
FAP 3 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 0 | 0 | 5 | 1.1m (867k to 1.3m) | 0.18* | |
EpCAM 3 cancers with incidence and prevalence data | 1 | 1 | 18 | 1.7m (1.5m to 2.0m) | 0.12 | |
TP53 14 cancers with incidence and prevalence data | 1 | 1 | 176 | 4.7m (3.7m to 5.8m) | 0.06 | |
| 12 | 7 | 529 | no incidence or prevalence data | n/a | ||
| 3 | 2 | 1,018 | no incidence or prevalence data | n/a | ||
| 5 | 0 | 427 | no incidence or prevalence data | n/a | ||
| 4 | 1 | 298 | no incidence or prevalence data | n/a | ||
| 2 | 2 | 115 | no incidence or prevalence data | n/a | ||
| 2 | 1 | 27 | no incidence or prevalence data | n/a | ||
| 3 | 1 | 1,571 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 1,947 | no incidence or prevalence data | n/a | ||
| 3 | 0 | 340 | no incidence or prevalence data | n/a | ||
| 1 | 1 | 33 | no incidence or prevalence data | n/a | ||
| 1 | 1 | 39 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 165 | no incidence or prevalence data | n/a | ||
| 2 | 1 | 1,203 | no incidence or prevalence data | n/a | ||
| 3 | 0 | 393 | no incidence or prevalence data | n/a | ||
| 3 | 0 | 144 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 158 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 52 | no incidence or prevalence data | n/a | ||
| 0 | 1 | 5 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 204 | no incidence or prevalence data | n/a | ||
| 0 | 1 | 6 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 5 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 119 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 60 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 1,209 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 50 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 33 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 205 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 415 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 93 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 3 | no incidence or prevalence data | n/a |
* Partial population: one or more of the target’s cancers (sarcoma, GIST, neuroendocrine tumours, neuroblastoma) has no GLOBOCAN site estimate and is excluded from the denominator, so the index is inflated. Read those rows as “crowded in the cancers we can count”.
crowding = active assets / (addressable patients per year / 100,000)
active assets = corpus products aimed at the target, excluding
negative, withdrawn and historic
addressable/year = sum over cancers with a prevalence figure of
GLOBOCAN incidence (world) x subtype share
x prevalence x first setting share, midpointThe population term is how many people a treatment could reach, run for the world with the broadest setting. Targets whose cancers have no GLOBOCAN estimate (sarcoma, neuroendocrine tumours) or no parseable prevalence get no index, not a zero.
A high index means many programmes per patient: TROP2, HER2 and PD-1 crowding is real and shows up here. It does not measure quality, differentiation or the odds any one asset wins, and it counts only what is in this corpus, so thinly covered targets look less crowded than they are. Registry study counts include combination trials under each product named, so they overstate distinct trials.
Statuses come from product records (checked on the date each product record was last reviewed); registry counts were fetched 2026-09-28.